Table 5. Results of typing of neutralizing antibodies in serum from patients with Dobrava-Belgrade virus–associated hemorrhagic fever with renal syndrome, Russia.

Region	Sample no.	Time after onset of disease	FRNT titer* against
			Sochi/Ap	Lipetsk/Aa	Slo/Af	SK/Aa	HTNV	SEOV	PUUV
Sochi (2000–2006)	1,312	104 d	2,560	80	160	ND	160	<80	<40
	3,692	30 d	1,280	160	160	ND	<80	<80	<40
	1,291	16 d	640	160	160	ND	40	40	<40
	4,714	1 y, 5 mo	>20,480	5,120	5,120	ND	320	320	<40
	1,310	50 d	2,560	640	640	ND	160	160	<40
	1,307	15 d	640	320	320	ND	160	160	<40
	4,716	5 y, 3 mo	5,120	1,280	2,560	ND	160	<80	<40
	4,715	1 y, 4 mo	5,120	2,560	5,120	ND	ND	ND	<40
Lipetsk (2001–2002)	4,338	6 mo	160	640	160	320	ND†	ND†	ND†
	3,894	21 d	40	640	40	160	ND†	ND†	ND†
	4,334	3 y, 6 mo	160	640	320	160	ND†	ND†	ND†
	4,344	6 mo	160	640	320	640	ND†	ND†	ND†
	3,958	3 mo	20	80	80	40	ND†	ND†	ND†
	4,329	3 y, 4 mo	640	640	2,560	640	ND†	ND†	ND†
Slovakia	B38	3 y, 9 mo	2,560	640	5,120	2,560	40	640	40
	B39	3 y, 9 mo	2,560	1,280	10,240	2,560	160	160	40

*FRNT, focus-reduction neutralization test. Reciprocal end-point titers are given as determined by chemiluminescence FRNT. ND, not determined.
†Serum previously characterized as anti–Dobrava-Belgrade virus (DOBV) in a first FRNT investigation with Hantaan virus (HTNV), Seoul virus (SEOV), Puumala virus (PUUV), and DOBV–Slo/Af only.